Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HCW Biologics Inc.HCWB · Entity 8172 | Director | May 16, 2025 | May 20, 2025 |
| LENSAR, Inc.LNSR · Entity 6733 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HCW Biologics Inc.
Report date May 16, 2025 · Filed May 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,075 |
Reported balance
After 2025-05-16 transaction · row 1
1 source rowRow 1 · 2025-05-16 · Purchase · Acquired 1,342 · Balance 4,075 F1: These shares were issued pursuant to a conversion of Unsecured Convertible Promissory Notes which were issued to six holders through a Company financing of an aggregate principal of $270,000 in one-year Notes. The Notes contained a mandatory conversion provision, which resulted in the Notes converting into shares of common stock at a mandatory conversion price of $7.45 per share as set by the registered offering. The Notes converted after the closing of the Company's registered offering on May 15, 2025. The conversion transaction also included an allocated portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued pursuant to a conversion of Unsecured Convertible Promissory Notes which were issued to six holders through a Company financing of an aggregate principal of $270,000 in one-year Notes. The Notes contained a mandatory conversion provision, which resulted in the Notes converting into shares of common stock at a mandatory conversion price of $7.45 per share as set by the registered offering. The Notes converted after the closing of the Company's registered offering on May 15, 2025. The conversion transaction also included an allocated portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company.
LENSAR, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,635 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,421 · Balance 105,635 F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2022 Filed May 28, 2022 00:01 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 15,616 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020022 · doc4.xml · derivative · entry 2 Winer Gary M · CIK 0001822095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,616 Underlying: Common Stock · 15,616 shares Expires 2032-05-25 F2 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 25, 2022 Filed May 28, 2022 00:01 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 4,285 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020022 · doc4.xml · nonDerivative · entry 1 Winer Gary M · CIK 0001822095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,552 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2023, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| October 26, 2021 Filed Oct 29, 2021 00:14 UTC Amendment | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option · Derivative | 37,037 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-21-061979 · doc4a.xml · derivative · entry 1 Winer Gary M · CIK 0001822095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,037 Underlying: Common Stock · 37,037 shares Expires 2031-10-25 F1 · derivative.exercise_date: The option will fully vest on October 26, 2022. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 21:14 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option · Derivative | 30,037 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-21-061923 · doc4.xml · derivative · entry 1 Winer Gary M · CIK 0001822095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,037 Underlying: Common Stock · 30,037 shares Expires 2031-10-25 F1 · derivative.exercise_date: The option will fully vest on October 26, 2022. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:15 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 20,847 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0000899243-21-020144 · doc4.xml · derivative · entry 1 Winer Gary M · CIK 0001822095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,847 Underlying: Common Stock · 20,847 shares Expires 2031-05-18 F1 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 18, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| December 07, 2020 Filed Dec 11, 2020 01:54 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 4,026 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-033402 · doc4.xml · nonDerivative · entry 1 Winer Gary M · CIK 0001822095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,267 Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 23:00 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 51 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027748 · doc4.xml · nonDerivative · entry 1 Winer Gary M · CIK 0001822095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,241 F1 · kind: Represents shares acquired from the Issuer as a result of a provision contained in the Reporting Person's restricted stock award agreement intended to maintain certain target ownership percentages of the Issuer's common stock in connection with the spin-off transaction. F1 · shares: Represents shares acquired from the Issuer as a result of a provision contained in the Reporting Person's restricted stock award agreement intended to maintain certain target ownership percentages of the Issuer's common stock in connection with the spin-off transaction. F2 · balance_after: Includes 20,130 shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.